A. Bryskier

发表

In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia.

M. Wolff, R. Farinotti, Claude Carbón, 2000, The Journal of antimicrobial chemotherapy.

Activities of a New Oral Streptogramin, XRP 2868, Compared to Those of Other Agents against Streptococcus pneumoniae and Haemophilus Species

M. Jacobs, A. Bryskier, P. Appelbaum, 2003, Antimicrobial Agents and Chemotherapy.

In Pursuit of New Antibiotics

A. Bryskier, 2005 .

Resistance to β-Lactams, a Self-Regenerating Problem

J. Aszodi, A. Bryskier, 2001 .

R. Lütticken, A. Bryskier, R. Reinert, 2004, Antimicrobial Agents and Chemotherapy.

The AcrAB-TolC Pump Is Involved in Macrolide Resistance but Not in Telithromycin Efflux in Enterobacter aerogenes and Escherichia coli

J. Pagés, R. Chollet, A. Bryskier, 2004, Antimicrobial Agents and Chemotherapy.

Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany.

N. D. Truong, R. Lütticken, A. Bryskier, 2001, Microbial drug resistance.

Anti-anaerobic activity of antibacterial agents

A. Bryskier, 2001, Expert opinion on investigational drugs.

In Vitro Activities of Telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, andEhrlichia chaffeensis

D. Raoult, J. Rolain, A. Bryskier, 2000, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of the New Ketolide Telithromycin Compared with Those of Macrolides against Streptococcus pyogenes: Influences of Resistance Mechanisms and Methodological Factors

H. Drugeon, G. Schito, A. Bryskier, 2000, Antimicrobial Agents and Chemotherapy.

Roxithromycin: review of its antimicrobial activity.

A. Bryskier, 1998, The Journal of antimicrobial chemotherapy.

Helicobacter pylori and Antibacterial Agents

A. Bryskier, J. Lowther, C. Couturier, 2005 .

Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine

Nalin Rastogi, A. Bryskier, K. S. Goh, 1996, Antimicrobial agents and chemotherapy.

In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase Inhibitor, in a Murine Candidiasis Model

D. Andes, K. Marchillo, A. Bryskier, 2003, Antimicrobial Agents and Chemotherapy.

The etiology of respiratory tract infections and the antibacterial activity of fluoroquinolones and other oral antibacterial agents against respiratory pathogens.

M. Jacobs, G. Schito, F. Goldstein, 1998, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Macrolide-Resistant Streptococcus pneumoniae and Streptococcus pyogenes in the Pediatric Population in Germany during 2000-2001

R. Lütticken, A. Bryskier, R. Reinert, 2003, Antimicrobial Agents and Chemotherapy.

Activities of HMR 3787 and RU 64399 Compared with Those of Four Other Agents against Haemophilus influenzae and Haemophilus parainfluenzae

M. Jacobs, A. Bryskier, B. Bozdoğan, 2003, Antimicrobial Agents and Chemotherapy.

Antigenic specificities of various antiribosomal antibodies detected in the serum of patients with systemic lupus erythematosus and other related diseases

A. Bryskier, M. Labro, J. Homberg, 1982, Rheumatology International.

Epidemiology of Resistance to Antibacterial Agents

A. Bryskier, 2005 .

Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.

H. Drugeon, A. Bryskier, M. Juvin, 1999, The Journal of antimicrobial chemotherapy.

Mechanisms of Macrolide Resistance in Clinical Pneumococcal Isolates in a University Hospital, Ankara, Turkey

D. Gür, A. Bryskier, B. Şener, 2005, Journal of chemotherapy.

New research in macrolides and ketolides since 1997.

A. Bryskier, 1999, Expert opinion on investigational drugs.

Activities of a New Fluoroketolide, HMR 3787, and Its (Des)-Fluor Derivative RU 64399 Compared to Those of Telithromycin, Erythromycin A, Azithromycin, Clarithromycin, and Clindamycin against Macrolide-Susceptible or -Resistant Streptococcus pneumoniae and S. pyogenes

A. Bryskier, L. Ednie, P. Appelbaum, 2001, Antimicrobial Agents and Chemotherapy.

CHAPTER 22 – Macrolides

A. Bryskier, 2010 .

Comparative Activities of Telithromycin (HMR 3647), Levofloxacin, and Other Antimicrobial Agents against Human Mycoplasmas

A. Bryskier, C. Bébéar, C. Bébéar, 2000, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of faropenem, a new oral penem, against lower respiratory tract pathogens.

A. Marchese, E. Debbia, G. Schito, 1999, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Antibiotic Susceptibilities of Parachlamydia acanthamoeba in Amoebae

D. Raoult, M. Maurin, A. Bryskier, 2002, Antimicrobial Agents and Chemotherapy.

Cephems: fifty years of continuous research.

A. Bryskier, 2000, The Journal of antibiotics.

The bactericidal activities of HMR 3004, HMR 3647 and erythromycin against gram-positive bacilli and development of resistance.

F. Soriano, J. Esteban, R. Calvo, 1999, The Journal of antimicrobial chemotherapy.

In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus

J. Frean, K. Klugman, A. Bryskier, 1996, Antimicrobial agents and chemotherapy.

Treatment of acute Chlamydia pneumoniae infection with telithromycin in C57BL/6J mice.

M. Leinonen, P. Saikku, A. Bryskier, 2004, The Journal of antimicrobial chemotherapy.

DNA Gyrase Inhibitors Other Than Fluoroquinolones

A. Bryskier, 2005 .

Antifungal Targets and Research into Antifungal Agents

A. Bryskier, 2005 .

Anti-MRSA agents: under investigation, in the exploratory phase and clinically available

A. Bryskier, 2005, Expert review of anti-infective therapy.

Agents against Methicillin-Resistant Staphylococcus aureus

A. Bryskier, 2005 .

Classification of oral cephalosporins. A matter for debate.

J. Williams, I. Gould, K. Naber, 2001, International journal of antimicrobial agents.

Activity of Levofloxacin, Ofloxacin, D-Ofloxacin and Ciprofloxacin against Systemic and Respiratory Tract Infections in Laboratory Animals

G. Riess, A. Bryskier, G. Seibert, 2012, Drugs.

Macrolide Resistance of Streptococcus pyogenes

G. Cornaglia, A. Bryskier, 2004 .

Bacillus anthracis and antibacterial agents.

A. Bryskier, André Bryskier, 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

In-vitro antimicrobial activity of HMR 3004 (RU 64004) against erythromycin A-sensitive and -resistant Corynebacterium spp. isolated from clinical specimens.

F. Soriano, R. Calvo, A. Bryskier, 1998, The Journal of antimicrobial chemotherapy.

Pharmacokinetic study of cefmenoxime (SCE 1365-CMX) in healthy adults.

J. Fourtillan, A. Bryskier, G. Humbert, 1984, The American journal of medicine.

Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex

Nalin Rastogi, A. Bryskier, K. S. Goh, 1994, Antimicrobial Agents and Chemotherapy.

In vitro activity of roxithromycin against 16 species of atypical mycobacteria and effect of pH on its radiometric MICs

Nalin Rastogi, A. Bryskier, K. S. Goh, 1993, Antimicrobial Agents and Chemotherapy.

InVitro Activity ofRoxithromycin against 16Species of Atypical Mycobacteria andEffect ofpH on ItsRadiometric MICs

Nalin Rastogi, A. Bryskier, K. S. Goh, 1993 .

A Bryskier Mycobacterium avium complex . amikacin , ofloxacin , and clofazimine against combination with ethambutol , rifampin , Activities of roxithromycin used alone and in

Nalin Rastogi, A. Bryskier, K. S. Goh, 2022 .

The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection

T. Slifer, J. Remington, F. Araújo, 1997, Antimicrobial agents and chemotherapy.

Glycopeptides and Lipoglycopeptides

A. Bryskier, P. Veyssier, 2005 .

Antimicrobial agents: antibacterials and antifungals.

A. Bryskier, 2005 .

In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis

Nalin Rastogi, A. Bryskier, K. S. Goh, 1996, Antimicrobial agents and chemotherapy.

Classification and Structure-Activity Relationships of Fluoroquinolones

A. Bryskier, J. Chantot, 2012, Drugs.

Section Review: Anti-infectives: Penems: new oral β-lactam drugs

A. Bryskier, 1995 .

In Vitro Activities of the New Ketolide Antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany

R. Lütticken, A. Bryskier, R. Reinert, 1998, Antimicrobial Agents and Chemotherapy.

In Vitro Susceptibilities of Bordetella pertussis and Bordetella parapertussis to Two Ketolides (HMR 3004 and HMR 3647), Four Macrolides (Azithromycin, Clarithromycin, Erythromycin A, and Roxithromycin), and Two Ansamycins (Rifampin and Rifapentine)

A. Bryskier, J. Hoppe, 1998, Antimicrobial Agents and Chemotherapy.

Novelties in the field of macrolides.

A. Bryskier, 1997, Expert opinion on investigational drugs.

Parenteral cephalosporin classification

J. Aszodi, A. Bryskier, J. Chantot, 1994 .

Novelties in the field of anti-infective compounds in 1999.

A. Bryskier, A Bryskier, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In Vitro Evaluation of Faropenem Activity Against Anaerobic Bacteria

A. Bryskier, L. Dubreuil, J. Behra-Miellet, 2005, Journal of chemotherapy.

Dual beta-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatment.

A. Bryskier, 1997, Expert opinion on investigational drugs.

In Vitro Activities of the Ketolides Telithromycin (HMR 3647) and HMR 3004 Compared to Those of Clarithromycin against Slowly Growing Mycobacteria at pHs 6.8 and 7.4

Nalin Rastogi, A. Bryskier, K. S. Goh, 2000, Antimicrobial Agents and Chemotherapy.

β-Lactamase Inhibitors Under Research

A. Bryskier, J. Lowther, C. Couturier, 2005 .

Effect of RU004 on oxidant production by human neutrophils

A. Bryskier, M. Labro, H. Abdelghaffar, 1996 .

Interactions between HMR 3647, a New Ketolide, and Human Polymorphonuclear Neutrophils

A. Bryskier, M. Labro, A. Preira, 1998, Antimicrobial Agents and Chemotherapy.

Ketolides: novel antibacterial agents designed to overcome resistance to erythromycin A within gram-positive cocci

A. Bryskier, A. Denis, 2002 .

New medical targets for macrolides

A. Bryskier, C. Agouridas, J. Chantot, 1994 .

Ketolides-telithromycin, an example of a new class of antibacterial agents.

A. Bryskier, 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Peptidyl Deformylase Inhibitors

A. Bryskier, J. Lowther, 2005 .

Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex.

H. Drugeon, A. Bryskier, P. Bémer-Melchior, 2000, The Journal of antimicrobial chemotherapy.

Cefodizime, a new 2-aminothiazolyl cephalosporin: physicochemical properties, toxicology and structure-activity relationships.

A. Bryskier, M. Labro, T. Procyk, 1990, Journal of Antimicrobial Chemotherapy.

Perfecting the ring and extending the antibacterial spectrum: 'the multiple generations'.

A. Bryskier, 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

New concepts in the field of cephalosporins: C-3' quaternary ammonium cephems (Group IV)

A. Bryskier, 1997 .

Novelties in the field of anti-infectives in 1997.

A. Bryskier, A Bryskier, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Development of an Antibiotic: Microbiology

A. Bryskier, 2005 .

Antituberculosis Compounds Under Investigation

A. Bryskier, 2005 .

Combination effect of cefmenoxime with four aminoglycosides on Enterobacteriaceae susceptible and moderately susceptible to this new cephalosporin.

H. Leclerc, A. Bryskier, D. Izard, 1984, Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology.

Dihydrofolate Reductase Inhibitors, Nitroheterocycles (Furans), and 8-Hydroxyquinolines

A. Bryskier, P. Veyssier, 2005 .

Pharmacokinetics of cefotiam administered intravenously and intramuscularly to healthy adults

J. Fourtillan, A. M. Brisson, L. Millérioux, 1984, Antimicrobial Agents and Chemotherapy.

Antibacterial activity of ofloxacin and other 4-quinolone derivatives: in-vitro and in-vivo comparison.

A. Bryskier, J. Chantot, 1985, The Journal of antimicrobial chemotherapy.

The suppository form of antibiotic administration: pharmacokinetics and clinical application.

E. Bergogne-Bérézin, A. Bryskier, 1999, The Journal of antimicrobial chemotherapy.

Microbial Efflux of Antibiotics and Inhibitors of Efflux Pumps

A. Bryskier, 2005 .

Tetracyclines Under Investigation

A. Bryskier, 2005 .

Antibacterial activity of roxithromycin: a laboratory evaluation.

A. Bryskier, J. Chantot, J. Gasc, 1986, The Journal of antibiotics.

Fluoroquinolones and Tuberculosis: a Review

A. Bryskier, J. Lowther, 2005 .

Fluoroquinolones and tuberculosis

A. Bryskier, J. Lowther, 2002, Expert opinion on investigational drugs.

Novelties in the field of fluoroquinolones.

A. Bryskier, 1997, Expert opinion on investigational drugs.

In Vitro Activities of a New Lipopeptide, HMR 1043, against Susceptible and Resistant Gram-Positive Isolates

H. Drugeon, P. Bémer, A. Bryskier, 2003, Antimicrobial Agents and Chemotherapy.

Diffusion of Ofloxacin into Human Lung Tissue

L. Couraud, J. Fourtillan, M. Saux, 2012, Drugs.

Viridans group streptococci: a reservoir of resistant bacteria in oral cavities.

A. Bryskier, André Bryskier, 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages

Nalin Rastogi, A. Bryskier, V. Labrousse, 1995, Antimicrobial agents and chemotherapy.

human macrophages . against Mycobacterium avium complex in alone and in association with other drugs Intracellular activities of roxithromycin used

Nalin Rastogi, A. Bryskier, V. Labrousse, 1995 .

[Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].

A. Bryskier, J. Robert, J. Croizé, 1985, Pathologie-biologie.

Effect of Proinflammatory Cytokines on the Interplay between Roxithromycin, HMR 3647, or HMR 3004 and Human Polymorphonuclear Neutrophils

A. Bryskier, M. Labro, D. Vazifeh, 2000, Antimicrobial Agents and Chemotherapy.

Comparative In Vitro Activities of XRP 2868, Pristinamycin, Quinupristin-Dalfopristin, Vancomycin, Daptomycin, Linezolid, Clarithromycin, Telithromycin, Clindamycin, and Ampicillin against Anaerobic Gram-Positive Species, Actinomycetes, and Lactobacilli

E. Goldstein, D. Citron, A. Bryskier, 2005, Antimicrobial Agents and Chemotherapy.

[Evaluation of the extravascular distribution of cefotiam (SCE 963) by the skin blister technic].

J. Ortonne, J. Fourtillan, A. Bryskier, 1984, Pathologie-biologie.

Coumarin Antibiotics: Novobiocin, Coumermycin, and Clorobiocin

A. Bryskier, M. Klich, 2005 .

Update Anti-infectives Novelties in the field of macrolides

A. Bryskier, 1997 .

Antibiotics and Antibacterial Agents: Classifications and Structure-Activity Relationship

A. Bryskier, 2005 .

Novelties in the field of anti-infectives in 1998.

A. Bryskier, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.

F. Derouin, A. Bryskier, S. Romand, 1995, The Journal of antimicrobial chemotherapy.

Effect of pH on the susceptibility of Helicobacter pylori to the ketolide telithromycin (HMR 3647) and clarithromycin.

C. Soussy, C. Lascols, A. Bryskier, 2001, The Journal of antimicrobial chemotherapy.

Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers

B. Lenfant, A. Bryskier, F. Namour, 1995, Antimicrobial agents and chemotherapy.

Pharmacokinetics of cefodizime administered intravenously as a single-dose (1.0 and 2.0 g) to healthy adult volunteers.

J. Fourtillan, B. Lenfant, A. Bryskier, 1990, The Journal of antimicrobial chemotherapy.

Bactericidal activity of cefodizime on Enterobacteriaceae in an in-vitro model simulating plasma pharmacokinetics in humans.

A. Péchinot, A. Bryskier, A. Kazmierczak, 1997, The Journal of antimicrobial chemotherapy.

What is the Current Role of Macrolides and Ketolides in the Treatment of Group A Streptococcal Pharyngitis

G. Cornaglia, A. Bryskier, 2004 .

In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin

K. Klugman, A. Bryskier, T. Capper, 1996, Antimicrobial agents and chemotherapy.

Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.

N Rastogi, Nalin Rastogi, A. Bryskier, 2000, The Journal of antimicrobial chemotherapy.

β-Lactam Prodrugs

A. Bryskier, 2005 .

Antibacterial activity of RU44790, a new N-tetrazolyl monocyclic beta-lactam

G. Teutsch, P. Collette, A. Bryskier, 1992, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens.

G. Drusano, A. Bryskier, R. Nusrat, 2005, Diagnostic microbiology and infectious disease.

Peptidoglycan Synthesis Inhibitors

C. Dini, A. Bryskier, 2005 .

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

A. Bryskier, 1995 .

In-vitro antibacterial activity of levofloxacin against hospital isolates: a multicentre study.

P. Courvalin, C. Soussy, M. Kitzis, 1999, Journal of Antimicrobial Chemotherapy.

Anti-pseudomonal activity of HR 810

H. Leclerc, A. Bryskier, D. Izard, 1985, Infection.

Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.

J. Remington, F. Araújo, A. Bryskier, 1998, The Journal of antimicrobial chemotherapy.

Mechanism Underlying Levofloxacin Uptake by Human Polymorphonuclear Neutrophils

A. Bryskier, M. Labro, D. Vazifeh, 1999, Antimicrobial Agents and Chemotherapy.

by Human Polymorphonuclear Neutrophils Mechanism Underlying Levofloxacin Uptake

A. Bryskier, M. Labro, D. Vazifeh, 1999 .

Novelties in the field of parenteral cephem antibacterials since 1993.

A. Bryskier, 1997, Expert Opinion on Investigational Drugs.

Ofloxacin: antibacterial activity, induction of resistance and killing curves.

H. Leclerc, A. Bryskier, D. Izard, 1985, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.

[Diffusion of ofloxacin in human lung tissue].

L. Couraud, J. Fourtillan, M. Saux, 1986, Infection.

Roxithromycin: review of its antimicrobial activity.

A. Bryskier, 1998, The Journal of antimicrobial chemotherapy.

A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae.

R. Lütticken, A. Bryskier, R. Reinert, 1999, The Journal of antimicrobial chemotherapy.

Pseudomonas aeruginosa: Alterations Induced by Low Concentrations of 4-Quinolones

A. Bryskier, J. Hakim, M. Labro, 1989 .